Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001738048-26-000032
Filing Date
2026-02-17
Accepted
2026-02-17 18:20:21
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 17251
  Complete submission text file 0001738048-26-000032.txt   19277
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Subject) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-58467 | Film No.: 26644270
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 530 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10036
Business Address 530 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10036 212-444-4100
Venrock Healthcare Capital Partners III, L.P. (Filed by) CIK: 0001738048 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A